We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
AIE-pharmacology-enabled organelle therapeutics for microplastic-induced asthenozoospermia
Summary
Scientists have discovered that tiny plastic particles from PTFE (a common non-stick and waterproof coating material) can damage sperm by harming cell "batteries" (mitochondria) and triggering a harmful process called ferroptosis, contributing to male infertility. In mice, researchers created a new treatment combining healthy mitochondria with a natural plant compound that both repairs cellular energy production and blocks this damaging process, successfully restoring sperm count and movement. While this is early-stage animal research, it points to a promising new strategy for combating fertility problems linked to everyday plastic pollution exposure.
Microplastic pollution, particularly from polytetrafluoroethylene (PTFE), is an emerging threat to male fertility, driving spermatogenic impairment and asthenozoospermia through mitochondrial failure and ferroptosis-two interconnected pathologies that current therapies fail to address together. Herein, we introduce an "AIE-Pharmacology" strategy that transforms the natural product Hydroxysafflor Yellow A (HSYA) into a unique theranostic agent. We discover that HSYA possesses intrinsic aggregation-induced emission (AIE) properties, establishing a seamless "Drug-Probe Unity" wherein anti-ferroptotic pharmacology and self-reporting fluorescence are fused within a single molecule. Leveraging this attribute, we engineer living, functional mitochondria with HSYA to construct a bio-hybrid platform-Mito@H. This platform embodies a conceptual leap: mitochondria are no longer passive delivery vehicles but active therapeutic units that execute metabolic reprogramming by restoring NAD/NADH redox balance and ATP synthesis, while the anchored HSYA concurrently suppresses ferroptosis via activation of the Nrf2/HO-1/SLC7A11/GPX4 axis. In a clinically relevant murine model of PTFE microplastic-induced asthenozoospermia, Mito@H administration strikingly rescues sperm count, progressive motility, and kinematic parameters, reconstitutes the complete spermatogenic lineage from spermatogonia to elongated spermatids, and reestablishes testicular redox homeostasis. This work pioneers a paradigm of organelle therapeutics powered by AIE-Pharmacology, offering a potent, precise, and translatable strategy to combat environmental toxicant-related male infertility and beyond.